Investor Relations

The Share

The Diamyd Medical share is traded on Nasdaq First North (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North

Nasdaq First North is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399.

Press Releases

Annual Report

  October 25, 2018

CEO Comments

Read More
  Annual Report, October 25, 2018

Dear Shareholders and readers

Insulin was discovered in 1921, a discovery that has since saved the lives of millions of people with type 1 and type 2 diabetes around the world. Today, almost 100 years after this pioneering discovery, and despite major progress in new insulin technologies and technical aids, fatality statistics are still anything but encouraging.
In Sweden, where we have access to the best possible diabetes care, life expectancy for children diagnosed with type 1 diabetes before the age of 10...

Both Diamyd® and Remygen® are at an exciting stage with an opportunity to reach the market faster than would otherwise be expected for drugs at the same development phase.
Ulf Hannelius, President and CEO

Calendar

  
January 23, 2019
Quarterly Report I
Quarterly Report 1 2018/2019
March 27, 2019
Quarterly Report II
Quarterly Report 2 2018/2019
June 26, 2019
Quarterly Report III
Quarterly Report 3 2018/2019
October 2, 2019
Year-End Report
Year-End Report 2018/2019
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of September 28, 2018

ShareholderA SharesB SharesCapital %Votes %
Essen-Möller, Anders 2 130 186 6 110 867 14.63 36.31
Avanza Pension 6 631 773 11.77 8.78
Lindkvist, Bertil 6 160 000 10.93 8.16
Nordnet Pension 2 172 134 3.86 2.88
Hansen, Patrik 1 520 000 2.70 2.01
Swedbank Försäkring 918 842 1.63 1.22
Arandi Development AB 500 000 0.89 0.66
Konstruktions o Försäljningsaktiebolag 415 000 0.74 0.55
Relbo AB 396 292 0.70 0.52
Schelé, Sven 360 000 0.64 0.48
Remaining shareholders 29 018 810 51.5 38.4
Total 2 130 186 54 203 718 100.0 100.0

Annual Report

  October 25, 2018  
Download

Contact Us

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden
+46 8 661 00 26
+46 8 661 63 68

Subscribe

   

Follow Us

  ©